The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Peter Libby, MD, a cardiovascular specialist at Brigham and Women’s
Hospital in Boston, Massachusetts, USA, holds the Mallinckrodt
Professorship of Medicine at Harvard Medical School. He directed
Cardiovascular Medicine at Brigham and Women’s Hospital from 1998 to
2014. His areas of clinical expertise include general and preventive
cardiology. His current major research focus is the role of
inflammation in vascular diseases such as atherosclerosis. Prof. Libby
has a particular devotion to clinical translation. He instigated and
helped to lead the large scale Canakinumab Anti-Inflammatory
Thrombosis Outcomes Trial that provided clinical validation of the
role of inflammation in atherosclerosis.
Prof. Libby has received numerous research awards, including the Distinguished Scientist Award from the American College of Cardiology (ACC), the Gold Medal of the European Society of Cardiology, the Basic Research Prize of the American Heart Association, the Anitschkow Prize in Atherosclerosis Research of the European Atherosclerosis Society, the Ernst Jung Gold Medal for Medicine, and the Benditt Award from the North American Vascular Biology Organization.
Prof. Libby’s professional memberships include the Association of American Physicians, the American Society for Clinical Investigation, and honorary memberships in the British Atherosclerosis Society, the Japan Circulation Society, and the Japanese College of Cardiology. He has served as the president of the Association of University Cardiologists. He also has served as a volunteer for the American Heart Association, including chairman of several research committees and member of executive committees. Prof. Libby presided the ACC’s Research Peer Review Committee for two terms. He has frequently consulted for the US National Heart, Lung, and Blood Institute (NHLBI), including membership on the Board of Scientific Councillors. He directed the DW Reynolds Cardiovascular Clinical Research Center and two cycles of Leducq Foundation Awards and has received continuous funding from the NHLBI for several decades. He currently serves as the president of the International Atherosclerosis Society.
As an author and lecturer on cardiovascular medicine and atherosclerosis, Prof. Libby has published extensively in medical journals including Circulation, Journal of Clinical Investigation, Proceedings of the National Academy of Sciences, New England Journal of Medicine, and Nature. He is an editor of Braunwald’s Heart Disease and was the editor-in-chief of the current 12th edition. Prof. Libby has also contributed chapters on the pathogenesis, treatment, and prevention of atherosclerosis to many editions of Harrison’s Principles of Internal Medicine. He has held numerous visiting professorships and delivered more than 150 major named or keynote lectures throughout the world.
Prof. Libby earned his medical degree at the University of California, San Diego, and completed his training in internal medicine and cardiology at the Peter Bent Brigham Hospital (now Brigham and Women’s Hospital). He also holds an honorary MA degree from Harvard University, and three honorary doctorates.